EastMed is a Halifax based company incorporated to develop, manufacture and market medical devices. It is currently developing a new self-fitting incontinence pessary for women. Per the company, a Canadian Patent has been secured and a US patent is pending.
Missing: Eastmed's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Eastmed's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Eastmed
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Eastmed is included in 2 Expert Collections, including Beauty & Personal Care.
Beauty & Personal Care
Startups in the beauty & personal care space, including cosmetics brands, shaving startups, on-demand beauty services, salon management platforms, and more.
Smart Home & Consumer Electronics
This Collection includes companies developing smart home devices, wearables, home electronics, and other consumer electronics.
Latest Eastmed News
Aug 29, 2022
By John Solomou Nicosia [Cyprus] August 29 (ANI): The Russian invasion of Ukraine more than 6 months ago has caused a dramatic spike in natural gas prices and caused repeated energy shocks in Europe. The EU has accused Moscow of using energy as a weapon, while Russia denies this and blames western sanctions for the drop in exports. After Russian state-owned company Gazprom announced a three-day shutdown of North Stream Pipeline 1, natural gas futures linked to TTF, Europe’s wholesale gas price, increased sharply to EUR340 per megawatt hour due to supply fears. Gazprom, claiming that it has problems with its turbines, has already reduced flows through the Nord Stream pipeline to about 20 per cent of its capacity. As Europe has been desperately trying to find alternative sources to cover its energy needs, and as Gulf oil and gas producers have made it clear that they are unable to substantially increase their output and cover the energy shortfall facing the European continent, the European Union and individual countries have turned their attention to the Eastern Mediterranean gas finds. Significant quantities of natural gas were discovered in the Eastern Mediterranean mainly in Israel, Egypt and Cyprus in recent years and European leaders, who in the past did not give much attention to this, have now come to realize that the region can potentially become an alternative source to Russian gas for European countries, contributing to the diversification of Europe’s energy supply route. The sizeable quantities of offshore natural gas discovered in recent years within the Levantine Basin and further across the Eastern Mediterranean Sea can turn the region into an oil and gas production hub and supplier. Egypt, Israel, Cyprus, and more recently Greece, have at varying degrees developed their national energy research and exploitation programs with the aim to extract, use and export their seabed resources. Most countries in the Eastern Mediterranean with the notable exception of Turkey, established back in 2019 an intergovernmental organization called the East Mediterranean Gas Forum (EMGF), or simply EastMed, to coordinate the activities and cooperation of participating states on natural gas issues. The charter of the EMGF international organization was signed in September 2020 and entered into force on 9 March 2021. The participating countries in the EastMed are: Cyprus, Egypt, Israel, Italy, Greece Jordan, Palestine and France. One country that is notably absent from the EastMed organization and from regional cooperation in the energy field is Turkey, although its geographical position lends itself to transporting natural gas to Europe. This is basically due to the confrontational foreign policy followed by Turkey’s President Recep Tayyip Erdogan, who on several occasions sent Turkish Navy ships to disrupt gas exploration activities in the Cyprus exclusive economic zone and every day sends Turkish aircraft to fly over Greek islands, creating tensions with Greece. Moreover, in the last four years, diplomatic relations between Turkey and Israel were frozen and Erdogan repeatedly called Israel “a terrorist state” and accused it of killing children. So as long as Turkey was at loggerheads with Greece, Cyprus, Israel and Egypt, Ankara’s participation in the EMGF was out of the question. However, in the past few months, Erdogan made efforts to mend relations with Egypt and last week agreed with the Israeli government to restore diplomatic relations between the two countries. So, he may also want to end Turkey’s exclusion from energy cooperation in the Eastern Mediterranean and may even seek to join the EGMF. On 15 June 2022, it was announced at the EGMF that the EU, Egypt and Israel had reached a deal for the supply of natural gas to the EU. Under the deal, gas from Israel will be brought via a pipeline to the LNG terminal on Egypt’s Mediterranean coast and then it will be transported on tankers to Europe. It is estimated that Israel can export about 500 billion cubic meters of gas to Europe in the next 20 years. On August 22, the Cyprus Energy Ministry has announced that the world’s third-largest gas discovery in the last two years has been made in the Eastern Mediterranean, off the southwest coast of Cyprus by Eni of Italy and France’s Total consortium. The discovery is estimated to contain 2.5 trillion cubic feet of gas and is the second deposit discovered in the area. At the moment Cyprus does not have an LNG facility but hopes to access existing infrastructure in Egypt following a recent agreement to build a pipeline linking these significant gas finds with Egypt’s LNG export facilities, so production from them could be delayed for several years. These quantities, when they become available, together with those of Israel and Egypt could cover Europe’s energy needs and free the continent from its dependence on Russian gas. However, there are constraints to achieving this. Egypt must first expand the capacity of its LNG facilities in Damietta and Idku by adding more liquefaction trains, while LNG terminals in European countries do not have enough capacity to receive greatly increased supplies of natural gas. Moreover, there are political risks involved in the whole effort and surely Europe’s weaning off from Russian gas will not be an easy task or something that can be achieved in the space of a few months. It is also something that entails political risks. As Karen Young, of the Centre on Global Energy Policy, Columbia University, points out: “For Europe, more political risk is associated with disruptions of LNG deliveries and attacks on drilling infrastructure in the Eastern Mediterranean. The advent of more political risk to budding gas infrastructure in the East Mediterranean would signal a prolonged energy security threat to European supply sources, even before they have become firmly established as alternatives to Russian pipeline gas. (ANI) This report is auto-generated from ANI news service. ThePrint holds no responsibility for its content. Subscribe to our channels on YouTube & Telegram Support Our Journalism India needs fair, non-hyphenated and questioning journalism, packed with on-ground reporting. ThePrint – with exceptional reporters, columnists and editors – is doing just that. Sustaining this needs support from wonderful readers like you. Whether you live in India or overseas, you can take a paid subscription by clicking here .
Eastmed Frequently Asked Questions (FAQ)
Where is Eastmed's headquarters?
Eastmed's headquarters is located at 1721 Lower Water St., Halifax.
What is Eastmed's latest funding round?
Eastmed's latest funding round is Unattributed VC.
How much did Eastmed raise?
Eastmed raised a total of $1.5M.
Who are the investors of Eastmed?
Investors of Eastmed include BDC Venture Capital and Innovacorp.
Who are Eastmed's competitors?
Competitors of Eastmed include Uromedica, InnoMed Technologies, Coherex Medical, ConforMIS, Aptus Endosystems and 12 more.
Compare Eastmed to Competitors
Uromedica develops minimally invasive medical devices that treat unmet medical needs in the area of urinary incontinence and related disorders. Products (sold under the ACT and ProACT brands) are based on adjustable balloon technology. Conditions being treated are post-prostatectomy incontinence in men and stress incontinence in women (after earlier interventions have failed).
NanoPowers aims to develop artificial muscles for various implant indications. The Company has developed several animal proof of concepts, and is entering preclinical stages with devices aimed for the treatment of urinary and fecal incontinences.
Axial Biotech, founded in 2002 by a group of spine surgeons and geneticists, is focused on the use of genetics and the development of minimally invasive fusionless devices to advance the diagnosis and treatment of diseases and deformities of the human spine. Axial is a company to pursue DNA-based pre-symptomatic and prognostic tests for common spinal conditions which will augment current clinical and surgical practices. In its initial genetic product development initiative, Axial has made progress towards the discovery of a location in the human genome that is associated with adolescent idiopathic scoliosis. In addition, Axial's founders have developed five motion preserving, fusionless surgical devices (including such device currently being implanted in humans) that have the promise of expanding the current treatable scoliosis patient population by a factor of ten. Axial intends to use its genetic intellectual property in the development of bio-mechanical devices, and to apply its gene discovery/product development methodology to other spinal diseases. Axial (www.axialbiotech.com) is located in Salt Lake City, Utah.
Endogun Medical Systems Ltd. is a medical device company developing: EndoFast Reliant„ system for Pelvic Organ Prolapse repair.
InnerPulse develops minimally invasive devices for cardiac rhythm management
Arbor Surgical Technologies, Inc. with facilities located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a broad portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery. Arbor Surgical Technologies mission is to simplify cardiac valve surgery through the innovative development of a less invasive, unique implantation system and valves with superior performance and durability. Partnering with physicians, we will improve patient recovery by less invasive techniques and reduced surgery time. Ethical behavior with employees, surgeons, patients and suppliers is the keystone to our success.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.